U.S. Energy Services Stock News

NasdaqGS:XNET
NasdaqGS:XNETSoftware

Xunlei (XNET) One Off Gain Driven Margin Raises Questions For Bullish Narratives

Xunlei (NasdaqGS:XNET) just posted its latest FY 2025 numbers with Q3 revenue of US$125.9 million and basic EPS of US$8.78, supported by trailing 12 month EPS of US$20.36. The company has seen revenue move from US$79.8 million in Q3 2024 to US$125.9 million in Q3 2025, while basic EPS shifted from US$0.07 to US$8.78 over the same quarters, setting up a very large year over year earnings jump that includes a one off gain and feeds into a 4.6% net margin that investors will scrutinize for...
NYSE:GRDN
NYSE:GRDNHealthcare

Guardian Pharmacy Services (GRDN) Profitability Turn Reinforces Bullish Margin Narratives

Guardian Pharmacy Services (GRDN) has just wrapped up FY 2025 with Q4 revenue of US$397.6 million and basic EPS of US$0.33, alongside trailing 12 month revenue of about US$1.4 billion and EPS of US$0.79 as the business has moved into consistent profitability. The company has seen revenue lift from US$338.6 million and EPS of a US$0.17 loss in Q4 FY 2024 to US$397.6 million and EPS of US$0.33 in Q4 FY 2025, while trailing net income shifted from a US$110.0 million loss at FY 2024 year end to a...
NYSE:RHLD
NYSE:RHLDProfessional Services

Resolute Holdings Management (RHLD) Q3 Loss Tests Bullish High‑Margin Narrative

Resolute Holdings Management (RHLD) has put out a mixed set of FY 2025 numbers, with Q3 revenue at US$120.9 million and a small net loss of US$0.2 million, translating to basic EPS of US$0.03 loss per share. Over recent quarters the company has seen revenue move from US$103.9 million in Q1 FY 2025 to US$119.6 million in Q2 and US$120.9 million in Q3. EPS shifted from a US$0.39 loss to a US$0.07 loss and then to a US$0.03 loss, setting the backdrop for investors who are watching how much of...
NYSE:SRI
NYSE:SRIAuto Components

Stoneridge Q3 Loss Near US$9 Million Tests Turnaround Narratives For SRI

Stoneridge (SRI) has just reported third quarter FY 2025 results with revenue of US$210.3 million and a basic EPS loss of US$0.34, while net income excluding extra items was a loss of US$9.4 million. Over recent quarters, the company has seen revenue move between US$213.8 million and US$237.1 million with basic EPS ranging from a profit of US$0.10 to losses of roughly US$0.22 to US$0.34. The trailing twelve month figures show US$874.4 million of revenue paired with a net loss of US$32.0...
NasdaqCM:KARO
NasdaqCM:KAROSoftware

Did Cartrack’s Two Million SA Subscribers Just Shift Karooooo’s (KARO) Recurring SaaS Revenue Narrative?

Earlier this year, Karooooo’s subsidiary Cartrack announced it had surpassed two million active subscribers in South Africa, marking a key scale milestone for its mobility solutions platform. This subscriber threshold reinforces Cartrack’s entrenched position in its core market and highlights how product innovation and customer focus support its South African footprint. Next, we’ll examine how crossing two million South African subscribers could influence Karooooo’s investment narrative...
OTCPK:KCLI
OTCPK:KCLIInsurance

Kansas City Life Insurance (OTCPK:KCLI) Quarterly Profit Returns While TTM Losses Question Bullish Narratives

Kansas City Life Insurance (KCLI) has wrapped up FY 2025 with fourth quarter revenue of US$120.4 million, basic EPS of US$0.23 and net income of US$2.3 million, alongside trailing 12 month revenue of US$485.5 million and a net loss of US$20.8 million, which translates to basic EPS of a US$2.14 loss. Over recent quarters the company has seen revenue move between US$118.98 million and US$125.15 million, while quarterly EPS has ranged from a US$2.90 loss to a US$0.33 profit. This sets up a story...
OTCPK:INRE
OTCPK:INRERetail REITs

Inland Real Estate Income Trust (OTCPK:INRE) FFO Collapse Reinforces Bearish Narratives

Inland Real Estate Income Trust (INRE) has posted its FY 2025 numbers with Q4 total revenue of US$38.7 million and a basic EPS loss of US$0.12, alongside funds from operations of US$36.3 million in the red. This gives investors a mixed read on operating performance and cash generation. Over the past year, total revenue has held in a tight band around US$150 million on a trailing twelve month basis while basic EPS for the same period came in at a loss of US$0.31, underscoring a sustained loss...
NYSE:MG
NYSE:MGProfessional Services

Mistras Group (MG) One Off US$14.4 Million Loss Fuels Bearish Margin Narratives

Mistras Group (MG) just closed out FY 2025 with fourth quarter revenue of US$181.5 million and basic EPS of US$0.12, alongside trailing twelve month revenue of US$724.0 million and EPS of US$0.54 that were shaped by a reported net profit margin of 2.3%. Over recent periods, the company has seen quarterly revenue move from US$172.7 million in FY 2024 Q4 to US$195.5 million in FY 2025 Q3 before landing at US$181.5 million in FY 2025 Q4. Quarterly EPS ranged from a loss of US$0.10 in FY 2025 Q1...
NasdaqGS:TTGT
NasdaqGS:TTGTMedia

TechTarget (TTGT) Q4 Loss Narrows To US$0.13 EPS And Tests Bearish Profitability Narrative

TechTarget (TTGT) has just posted its FY 2025 numbers with Q4 revenue of US$140.7 million and a basic EPS loss of US$0.13, capping a trailing 12 month period that featured revenue of US$486.8 million and a basic EPS loss of US$14.06. Over recent quarters, the company has seen revenue move from US$99.9 million in Q4 FY 2024 to US$103.9 million in Q1 FY 2025, US$119.9 million in Q2, US$122.3 million in Q3 and US$140.7 million in Q4. Quarterly basic EPS losses shifted from US$0.90 to US$7.32,...
NYSE:BBW
NYSE:BBWSpecialty Retail

Build A Bear Workshop NYSE BBW Net Margin Strength Tests Slower Growth Narrative

Build A Bear Workshop (BBW) has just reported new figures for FY 2026, with third quarter revenue of US$122.7 million and basic EPS of US$0.62. Trailing twelve month figures show revenue of US$525.8 million and EPS of US$4.38 backed by net income of US$57.5 million. Over recent quarters the company has seen revenue move from US$119.4 million in Q3 2025 to US$150.4 million in Q4 2025 and then to US$128.4 million and US$124.2 million in Q1 and Q2 2026. Basic EPS was US$0.64, US$1.63, US$1.17...
NYSE:SEE
NYSE:SEEPackaging

Sealed Air Debt Redemptions Could Reshape Leverage And Investor Risk Profile

Sealed Air (NYSE:SEE) has announced its intention to redeem multiple senior notes, subject to the closing of a pending transaction. The planned redemptions would retire certain outstanding debt instruments once the transaction is completed. The company has outlined the expected redemption terms ahead of closing to give bondholders and shareholders clarity on next steps. For investors watching Sealed Air, the focus now is on how this conditional redemption plan fits with the company’s...
NYSE:WOR
NYSE:WORMachinery

Is Worthington Enterprises (WOR) Pricing Look Attractive After Recent Share Price Pullback

If you are looking at Worthington Enterprises and wondering whether the current share price reflects its true value, this article will walk you through what the numbers are actually saying. The stock last closed at US$46.99, after a 7 day return of a 9.9% decline, a 30 day return of an 18.8% decline, a year to date return of a 9.6% decline, but a 1 year return of 18.8% and a 3 year return of 47.2% that sits ahead of its 5 year return of 16.3%. Recent coverage around Worthington Enterprises...
NasdaqGS:MLCO
NasdaqGS:MLCOHospitality

A Look At Melco Resorts & Entertainment (NasdaqGS:MLCO) Valuation After The New Be A Dreamer Branding Launch

Melco Resorts & Entertainment (MLCO) is back in the spotlight after unveiling its new City of Dreams chapter, Be A Dreamer, featuring Jing Boran as Global Brand Ambassador and Tan Yuan Yuan as Friend of the Brand. See our latest analysis for Melco Resorts & Entertainment. Despite the new Be A Dreamer launch and branding push in Macau, Melco Resorts & Entertainment’s 30 day share price return of 13.08% and 90 day share price return of 32.93% show fading momentum, even as the 1 year total...
NasdaqGM:FOLD
NasdaqGM:FOLDBiotechs

Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance

If you are wondering whether Amicus Therapeutics at around US$14.37 is attractively priced or already reflecting a lot of optimism, you are in the right place to focus on what the numbers are actually saying about value. The stock's return profile, with 0.3% over the last 7 days, 0.5% over 30 days, 0.7% year to date and 61.6% over 1 year, suggests the market has been reassessing the company over different time frames. Recent news around Amicus Therapeutics has continued to center on its role...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

Zoetis Backs Vet Tech Training To Deepen Long Term Clinic Ties

Zoetis (NYSE:ZTS) is expanding its support for veterinary education by offering free Human Animal Bond Certification to veterinary technician students across the US. The program extends an existing scholarship initiative and now targets a broader segment of the veterinary care team. This move focuses on the relationship between people and animals, a core element of modern companion animal and livestock care. For investors watching NYSE:ZTS, this update fits within Zoetis’s role as a global...
NasdaqGS:TNYA
NasdaqGS:TNYABiotechs

Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration

Tenaya Therapeutics (TNYA) is back in focus after reporting a full year 2025 net loss of US$90.6 million, alongside fresh preclinical data and a new collaboration in cardiovascular and muscular disease programs. See our latest analysis for Tenaya Therapeutics. The recent MDA 2026 data for TN-301 and the new Alnylam collaboration appear to have sharpened market focus, with a 7 day share price return of 47.70% standing in contrast to a 36.86% decline over 90 days and a 3 year total shareholder...
NasdaqGS:CNTA
NasdaqGS:CNTABiotechs

Why Centessa Pharmaceuticals (CNTA) Is Up 5.7% After Advancing ORX750 Toward Registrational Sleep-Disorder Trials

Centessa Pharmaceuticals recently reported past Phase II progress for its orexin agonist ORX750 in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, highlighting clinically meaningful effects alongside a favorable safety and tolerability profile. The company also outlined plans for registrational studies in rare hypersomnias, expanded its open-label extension to four weeks, and began preparing for regulatory engagement and commercial build-out, underscoring how central ORX750...
NasdaqGS:NTSK
NasdaqGS:NTSKSoftware

Netskope (NTSK) Is Up 14.5% After Launching AI Security Suite And Issuing 2027 Guidance

Netskope, Inc. has reported its fourth-quarter 2026 results, with sales of US$196.33 million and a net loss of US$56.77 million, and unveiled guidance for fiscal 2027 alongside the launch of its Netskope One AI Security suite. The introduction of Netskope One AI Security, which combines agentic AI protection, guardrails, gateways, and red teaming in a unified platform, positions the company directly in the emerging market for securing generative and enterprise AI use. We’ll now examine how...
NYSE:AUB
NYSE:AUBBanks

Is Atlantic Union Bankshares’ (AUB) Options Surge Reframing Its Risk‑Reward Story For Institutional Investors?

Atlantic Union Bankshares Corporation recently presented at the 47th Annual Raymond James Institutional Investor Conference in Orlando, drawing fresh attention from institutional investors. This event coincides with elevated call-option implied volatility and more optimistic analyst views, highlighting growing interest in the bank’s earnings outlook and risk profile. We’ll now examine how this heightened options activity and analyst optimism interact with Atlantic Union Bankshares’ existing...
NasdaqGS:CPB
NasdaqGS:CPBFood

Campbell Soup (CPB) Q2 EPS Steady At US$0.65 Tests Bullish Margin Improvement Narrative

Campbell's (CPB) has just reported its latest results with Q2 2026 revenue of US$2.68 billion and basic EPS of US$0.65, setting the tone for how the rest of the year may shape up. Looking back over recent quarters, revenue has moved between US$2.29 billion in Q4 2024 and US$2.77 billion in Q1 2025, while basic EPS has ranged from a small loss of US$0.01 in Q4 2024 to US$0.73 in Q1 2025. This gives investors a clear view of how sales and earnings have tracked into this quarter. With net income...
NasdaqGM:AIRO
NasdaqGM:AIROAerospace & Defense

A Look At AIRO Group Holdings (AIRO) Valuation As It Prepares For Cantor 2026 Conference Presentation

Conference spotlight and why AIRO is on more investor radars AIRO Group Holdings (AIRO) is set to present at the 2026 Cantor Global Technology & Industrial Growth Conference on March 11 in New York, giving investors a closer look at its aerospace and defense business. With Co Founder and Executive Chairman Chirinjeev Baboo Kathuria, Chief Executive Officer Joe Burns and Chief Financial Officer Mariya Pylypiv on stage, the session could offer more detail on AIRO’s drone, avionics, training and...
NYSE:UTZ
NYSE:UTZFood

Utz Brands Debuts Protein Snacks As Share Price Trails Analyst Valuation

Utz Brands (NYSE:UTZ) presented new protein-enriched snacks and globally inspired flavors at Natural Products Expo West. The lineup includes Boulder Canyon Agave Sriracha kettle chips and a high protein snack range with gluten free, non GMO, and kosher options. The launch targets growing interest in snacks that combine higher protein content with bolder, globally influenced taste profiles. For investors watching NYSE:UTZ, the new products come at a time when the share price is around $7.52,...
NasdaqGS:CHRW
NasdaqGS:CHRWLogistics

C.H. Robinson’s 100 Trillion Data Points Reframe Its AI Advantage

C.H. Robinson Worldwide (NasdaqGS:CHRW) has publicly detailed the scale of its proprietary logistics dataset, which now feeds over 100 trillion real world data points into its Lean AI system. The expanded AI platform coordinates hundreds of AI agents that support millions of shipping decisions across global freight and logistics operations. The company reports measurable benefits for customers, including faster time to market and more consistent pickup performance. C.H. Robinson is putting...
NasdaqGS:CAPR
NasdaqGS:CAPRBiotechs

Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains?

Wondering whether Capricor Therapeutics at around US$33.57 is still offering value or has already priced in the story? This article will walk you through what the numbers are actually saying about the stock. The share price has been volatile, with returns of 31.6% over the past week, 33.3% over the past month, 18.6% year to date, and 156.8% over the last year, alongside a very large 3 year gain and a more than 5x gain over 5 years. Recent interest in Capricor Therapeutics has been shaped by...